← All medicines

Cancer medicines

Niraparib

Independent educational summary · Sources checked November 20, 2026

A PARP inhibitor used for selected ovarian, fallopian-tube or primary peritoneal cancer maintenance under current HRD or BRCA eligibility criteria. Older treatment indications should not be assumed current.

Profile scope: Niraparib. Confirm the exact product and route; formulations and combination products are not interchangeable.

Possible side effects

Nausea, constipation, fatigue, appetite loss, headache and sleep disturbance may occur.

Serious risks and warning signs

Marrow suppression, myelodysplastic syndrome or leukemia, hypertension and neurological complications are important risks. Fever, unusual bleeding, severe headache or visual changes needs urgent assessment.

A question for your healthcare team

Which molecular result supports maintenance, and what blood-count, blood-pressure and symptom-monitoring schedule is required?

What to do with this information

Discuss persistent or troubling symptoms with your prescriber or pharmacist. For severe breathing difficulty, collapse, a seizure, or inability to wake someone, seek emergency help. Read the linked medicine information for drug-specific instructions, including situations requiring immediate action. For routine treatment changes, consult your prescriber rather than changing your dose on your own. Follow the urgent action instructions above and in the linked medicine information.

Sources

Sources checked November 20, 2026. An original AI-assisted educational summary, not a complete adverse-effect or interaction list. This profile is part of the broader library expansion, not the original prescription-use ranking. Inclusion does not confirm current product availability or mean that risks outweigh benefits. This page has not been independently reviewed by a clinician.